# Novo Nordisk CagriSema clinical trial results > Live situation record from CLSTR: https://clstr.news/situations/novo-nordisk-cagrisema-clinical-trial-results > Updated: 2026-10-20T20:52:00.000Z. Sources: 7. Developments: 2. Novo Nordisk has released findings from Phase 3 clinical trials regarding its experimental medication, CagriSema, which combines cagrilintide and semaglutide to treat diabetes and obesity. Initial results from the Phase 3 REIMAGINE 5 study involving adults with type 2 diabetes showed that patients lost an average of 12.4% of their body weight over 60 weeks. This outperformed the 9.1% weight loss observed in patients treated with 5 mg of tirzepatide, though researchers noted it did not necessarily exceed the results of higher doses of Mounjaro. Subsequent post-trial analysis from the Phase 3 REDEFINE 1 trial, which included approximately 2,300 women, reported an average body weight reduction of 25% for those receiving a 2.4 mg combination of the drugs. Further analysis by reproductive stage indicated weight loss estimates of 26.7% for premenopausal women, 24.8% for perimenopausal women, and 23.1% for postmenopausal women. The medication also demonstrated links to reduced waist circumference across all studied groups. ## Timeline ### 2026-10-20: Novo Nordisk experimental drug CagriSema shows 25% weight loss in women Novo Nordisk's experimental drug CagriSema achieved an average 25% weight loss in women during a Phase 3 trial analysis, showing efficacy across different menopause stages. 5 sources. https://clstr.news/cluster/novo-nordisk-experimental-drug-cagrisema-shows-25-weight-loss-in-women ### 2026-09-21: Novo Nordisk CagriSema shows higher weight loss than Mounjaro in Phase 3 study Novo Nordisk's experimental drug CagriSema showed higher average weight loss than a 5 mg dose of Mounjaro in a Phase 3 study, while the rise of such drugs increases demand for skin-tightening plastic surgery. 2 sources. https://clstr.news/cluster/novo-nordisk-cagrisema-shows-higher-weight-loss-than-mounjaro-in-phase-3-study --- Cite as: Novo Nordisk CagriSema clinical trial results. CLSTR, https://clstr.news/situations/novo-nordisk-cagrisema-clinical-trial-results